drugset / Trial / NCT00090727

Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00090727

Phase 1 Unknown 45 enrolled Novacea
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purposes of this study are to determine: * the largest dose of AQ4N that can be safely given once a week for three weeks out of a 4 week cycle * the side effects of AQ4N when given on the above schedule * how much AQ4N is in the blood and urine at specific times after administration and how the body get rids of AQ4N * if AQ4N helps treat cancer

Timeline

Start
2004-08
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject BANOXANTRONE Small molecule Intravenous